Company news

CytoSorbents Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CytoSorb® Registered and Commercially Available in Singapore

May 24, 2021

CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

May 10, 2021

CytoSorbents Reports First Quarter 2021 Financial and Operational Results

May 3, 2021

CytoSorbents to Report Q1 2021 Operating and Financial Results

April 26, 2021

U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

April 18, 2021

CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

March 28, 2021

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery

March 15, 2021

CytoSorbents Announces 2020 Financial and Operational Results

March 8, 2021

CytoSorbents to Report Fiscal 2020 Operating and Financial Results

February 28, 2021

CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs

January 20, 2021

CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care

January 18, 2021

CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue

January 11, 2021

CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing

January 10, 2021

Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

January 3, 2021

CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing

December 16, 2020

CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank

December 9, 2020

CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients

November 24, 2020

CytoSorbents Reports Record Third Quarter 2020 Financial Results

November 3, 2020

CytoSorbents and Aferetica Announce European Union Approval of the PerLife™ System and ECOS-300CY™ PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant

October 13, 2020

CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions

September 20, 2020

CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020

September 10, 2020

CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively Enrolling

September 7, 2020

CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19

August 16, 2020

CytoSorbents Reports Record Second Quarter 2020 Financial Results

August 3, 2020

CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date

August 2, 2020

CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development

July 30, 2020

CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data

July 27, 2020

CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock

July 21, 2020

CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update

July 19, 2020

Correction: CytoSorbents Corporation

July 7, 2020

CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise

June 23, 2020

CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials

June 8, 2020

CytoSorbents Announces Virtual Annual Meeting

May 26, 2020

CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery

May 11, 2020

CytoSorbents Reports First Quarter 2020 Financial and Operational Results

May 4, 2020

CytoSorbents Promotes Vincent J. Capponi to President

May 3, 2020

CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program

April 28, 2020

Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer

April 26, 2020

Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery

April 19, 2020

U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection

April 12, 2020

CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care

March 30, 2020

CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama

March 24, 2020

CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities

March 11, 2020

CytoSorbents Announces 2019 Financial and Operational Results

March 4, 2020

CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits

March 1, 2020

CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection

February 18, 2020

CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

January 28, 2020

CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter

January 13, 2020

CytoSorbents Reports Third Quarter 2019 Financial Results

November 4, 2019

CytoSorbents Announces Additions to its International Clinical Team

November 3, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 78 decks. Every deck is listed under its year.